Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study ; volume:19 ; number:1 ; day:12 ; month:9 ; year:2024 ; pages:1-10 ; date:12.2024
Addiction science & clinical practice ; 19, Heft 1 (12.9.2024), 1-10, 12.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Stopka, Thomas J.
Rottapel, Rebecca
Friedmann, Peter D.
Pivovarova, Ekaterina
Evans, Elizabeth A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13722-024-00486-2
- URN
-
urn:nbn:de:101:1-2411262109275.347119177283
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Stopka, Thomas J.
- Rottapel, Rebecca
- Friedmann, Peter D.
- Pivovarova, Ekaterina
- Evans, Elizabeth A.
- SpringerLink (Online service)
Other Objects (12)
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables